Recent Data and Market Reaction: Can Gossamer Bio Deliver on Growth Hopes? If you have been eyeing Gossamer Bio (GOSS), this week’s developments might help you make a call. The company announced ...
Gossamer Bio, Inc. (NASDAQ:GOSS) shareholders will have a reason to smile today, with the analysts making substantial upgrades to this year's forecasts. The analysts have sharply increased their ...
Gossamer Bio's seralutinib shows promise for PAH and PH-ILD, with a clean long-term safety profile differentiating it from competitors like Winrevair. AVTE's AV-101 failed due to dose limitations and ...
SAN DIEGO--(BUSINESS WIRE)--Gossamer Bio, Inc. (Nasdaq: GOSS), a late-stage, clinical biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of ...
SAN FRANCISCO, April 17, 2026 /PRNewswire/ -- A securities class action lawsuit has been filed against Gossamer Bio, Inc. (NASDAQ: GOSS) and an executive, seeking to represent investors who purchased ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results